Format

Send to

Choose Destination
Am J Perinatol. 2019 Sep;36(11):1142-1149. doi: 10.1055/s-0038-1676483. Epub 2018 Dec 14.

Inhaled Epoprostenol for Pulmonary Hypertension Treatment in Neonates: A 12-Year Experience.

Author information

1
Department of Paediatrics, CHU de Québec, Université Laval, Québec City, Québec, Canada.
2
Division of Neonatology, Department of Paediatrics, CHU de Québec, Université Laval, Québec City, Québec, Canada.
3
Division of Pediatric Intensive Care, Department of Paediatrics, CHU de Québec, Université Laval, Québec City, Québec, Canada.
4
Department of Biostatistic, Centre de recherche du CHUQ, Université Laval, Québec City, Québec, Canada.
5
Division of Pediatric Cardiology, Department of Paediatrics, CHU de Québec, Québec City, Québec, Canada.
6
Department of Pharmacy, CHU de Québec, Université Laval, Québec City, Québec, Canada.

Abstract

BACKGROUND:

 Persistent pulmonary hypertension of the newborn (PPHN) occurs in 10% of neonatal respiratory insufficiency. To selectively reduce pulmonary vascular resistance, several treatments have been tried. Inhaled epoprostenol (iPGI2) has been used for 12 years in our institution for the management of refractory PPHN despite the gaps in the literature to support this use.

OBJECTIVES:

 The primary objective was to evaluate the efficacy of iPGI2 for PPHN. The secondary objectives were to describe its use in neonates and assess side effects.

STUDY DESIGN:

 This retrospective cohort study included infants < 28 days with PPHN treated with iPGI2 in the neonatal or pediatric intensive care units of our institution between 2004 and 2016.

RESULTS:

 We reviewed 43 patient' care episodes (mean gestational age of 36 weeks). This was an extremely ill population with 54% mortality rate. Oxygenation index improved significantly after 12-hour treatment (p = 0.047), with a rebound effect when discontinuing nebulization. By the end of the therapy, the fraction of inspired oxygen had significantly dropped (p = 0.0018). Echocardiographic markers tended to normalize during treatment. No potential side effects were reported.

CONCLUSION:

 In these sick newborns, we observed an improvement in PPHN under iPGI2 without significant adverse effects. To our knowledge, this is the largest neonatal cohort reported to have received iPGI2 for PPHN.

PMID:
30551229
DOI:
10.1055/s-0038-1676483

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center